Dainippon Sumitomo Plan Trials On Drug To Attack “Cancer Stem Cells”
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharmaceuticals plans for clinical trials on a new anti-cancer drug to attack “cancer stem cells” which according to recent reports are the origin of the disease, the Osaka-based company announced on Jan. 24.